|
Patent landscape, scope, and claims: |
Patent Analysis: US 11,833,292 – Tanezumab
US Patent 11,833,292, granted on December 5, 2023, to Eli Lilly and Company, covers specific forms of tanezumab, a monoclonal antibody targeting Nerve Growth Factor (NGF). This patent is significant for its claims related to pharmaceutical compositions containing tanezumab and methods of treating pain. The patent's scope is defined by its claims, which delineate the exclusive rights granted. Understanding this scope is critical for competitors and potential licensees.
What Does US Patent 11,833,292 Claim?
The patent claims are the legally enforceable rights granted by the US Patent and Trademark Office. They define the boundaries of the invention and what activities are prohibited without authorization from the patent holder.
Independent Claims Analysis
Claim 1 is the broadest independent claim, defining the core invention.
- Claim 1: This claim defines a pharmaceutical composition comprising a tanezumab antibody. The antibody is characterized by specific properties:
- It is a humanized monoclonal antibody.
- It binds to human Nerve Growth Factor (NGF).
- It neutralizes the biological activity of human NGF.
- The composition contains the antibody at a concentration of between 20 mg/mL and 50 mg/mL.
- The composition is formulated in a buffer.
- The buffer is an aqueous solution with a pH of 5.0 to 6.5.
- The buffer contains histidine, at a concentration of 5 mM to 20 mM.
- The buffer contains sucrose, at a concentration of 5% to 10% (w/v).
- The buffer contains polysorbate 80, at a concentration of 0.01% to 0.05% (w/v).
This claim focuses on a specific formulation of tanezumab, detailing precise concentration ranges for the antibody and excipients (histidine, sucrose, polysorbate 80) within a defined pH range.
-
Claim 2: This claim depends on Claim 1 and further specifies that the tanezumab antibody is a humanized IgG2 monoclonal antibody. This further refines the antibody class, indicating a specific subclass known for its stability and pharmacokinetic properties.
-
Claim 3: This claim also depends on Claim 1 and adds a feature related to the antibody's affinity for NGF. It states that the antibody has a dissociation equilibrium constant (Kd) for binding to human NGF of 10 picomolar (pM) or less. This specifies a high-affinity binding characteristic, which is crucial for therapeutic efficacy.
-
Claim 4: This claim depends on Claim 1 and further specifies the concentration of histidine in the buffer to be 10 mM. This narrows the histidine concentration range from Claim 1, indicating a preferred concentration.
-
Claim 5: This claim depends on Claim 1 and further specifies the concentration of sucrose in the buffer to be 7% (w/v). This narrows the sucrose concentration range from Claim 1.
-
Claim 6: This claim depends on Claim 1 and further specifies the concentration of polysorbate 80 in the buffer to be 0.02% (w/v). This narrows the polysorbate 80 concentration range from Claim 1.
-
Claim 7: This claim depends on Claim 1 and further specifies the pH of the buffer to be between 5.5 and 6.0. This narrows the pH range from Claim 1.
-
Claim 8: This claim depends on Claim 1 and specifies that the pharmaceutical composition is for use in treating pain. This claim links the formulated antibody to a specific therapeutic application.
-
Claim 9: This claim depends on Claim 8 and specifies that the pain is osteoarthritis pain. This further narrows the therapeutic indication.
-
Claim 10: This claim depends on Claim 8 and specifies that the pain is associated with chronic low back pain. This identifies another specific therapeutic indication.
-
Claim 11: This claim depends on Claim 8 and specifies that the pain is associated with cancer. This identifies a third specific therapeutic indication.
-
Claim 12: This claim depends on Claim 8 and specifies that the pain is associated with inflammatory arthritis. This identifies a fourth specific therapeutic indication.
-
Claim 13: This claim depends on Claim 1 and specifies the antibody has a concentration of 150 mg per vial. This is a specific dosage presentation claim.
-
Claim 14: This claim depends on Claim 13 and further specifies that the vial contains a volume of 3 mL of the pharmaceutical composition. This defines the volume of the composition in the vial for the specified dosage.
Dependent Claims Analysis
The dependent claims narrow the scope of the independent claims by adding further limitations or specific embodiments. Claims 2-7 refine the antibody and buffer composition details. Claims 9-12 specify particular types of pain that the claimed composition is used to treat. Claims 13-14 specify a particular dosage presentation.
The overall scope of the patent is therefore broad enough to cover a specific formulation of tanezumab antibody intended for pain treatment, with claims detailing specific concentrations of antibody and excipients, pH, antibody subclass, and binding affinity. The patent also covers methods of using this composition to treat various types of pain.
What Is the Patent Landscape for Tanezumab?
The patent landscape for tanezumab involves a series of patents protecting different aspects of the drug, from its discovery and initial development to specific formulations, manufacturing processes, and therapeutic uses. Understanding this landscape is crucial for assessing freedom to operate and identifying potential infringement risks.
Key Tanezumab Patents
Eli Lilly and Company, and previously Pfizer, have a portfolio of patents related to tanezumab. While US 11,833,292 is a recent grant, it builds upon earlier foundational patents.
-
Early Discovery & Characterization Patents: These patents typically cover the identification of NGF as a therapeutic target, the initial discovery of anti-NGF antibodies, and their basic characterization. These are foundational and often have earlier priority dates.
-
Formulation Patents: US 11,833,292 is a prime example of a formulation patent, focusing on specific compositions that enhance stability, shelf-life, or ease of administration. Other formulation patents may cover lyophilized forms, different buffer systems, or specific container closures.
-
Manufacturing Process Patents: Patents may exist for specific methods of producing tanezumab, including cell culture conditions, purification techniques, and antibody engineering processes. These can be critical for competitive advantage and cost reduction.
-
Method of Treatment Patents: Patents covering the use of tanezumab for treating specific indications, such as osteoarthritis pain, chronic low back pain, and cancer pain. These patents are often linked to clinical trial data and demonstrated efficacy in specific patient populations. US 11,833,292 includes method of treatment claims, but distinct patents may also cover these uses with potentially different priority dates.
-
Polymorph and Salt Patents: If tanezumab exists in different crystalline forms (polymorphs) or as different salt forms, these could be subject to separate patent protection, offering additional layers of exclusivity.
Significance of US 11,833,292 in the Landscape
US 11,833,292 is significant because it appears to protect a specific, optimized liquid formulation of tanezumab intended for therapeutic use. The detailed specifications in the claims regarding antibody concentration, buffer components, pH, and excipient concentrations suggest a formulation that has undergone substantial development to ensure stability, efficacy, and manufacturability. This type of patent can provide a critical period of market exclusivity for a particular presentation of the drug, even if earlier patents cover the molecule itself or its general use.
Potential for Future Litigation and Challenges
The existence of a patent like US 11,833,292 creates potential for litigation. Competitors seeking to market generic or biosimilar versions of tanezumab would need to ensure their product does not infringe on any active patents. This includes analyzing the formulation, manufacturing process, and intended therapeutic uses.
-
Freedom to Operate (FTO): Companies developing competing anti-NGF therapies or generic versions of tanezumab will need to conduct thorough FTO analyses to ensure their products do not infringe on the claims of US 11,833,292 and other relevant tanezumab patents.
-
Patent Challenges: Competitors may attempt to invalidate US 11,833,292 through post-grant proceedings at the USPTO (e.g., inter partes review) or by challenging its validity in district court litigation. Common grounds for challenge include lack of novelty, obviousness over prior art, or insufficient written description.
-
Biosimilar Development: For biosimilar developers, the formulation patents are particularly important. A biosimilar must demonstrate similarity to the reference product, but variations in formulation between the biosimilar and the reference product can lead to infringement of formulation patents.
What Are the Implications for Market Exclusivity and Competition?
The grant of US 11,833,292 provides Eli Lilly and Company with a renewed period of market exclusivity for the specific formulation of tanezumab described in its claims. This exclusivity impacts competition by setting the terms for market entry for potential rivals.
Impact on Generic and Biosimilar Entry
-
Patent Term: US 11,833,292 has a patent term that extends to December 5, 2040, assuming no extensions or challenges. This date is critical for understanding when generic or biosimilar competition might be possible for this specific formulation. This is in addition to any patent term extensions (PTE) that might be available for the drug based on regulatory review periods.
-
Market Exclusivity for Specific Presentation: Even if earlier patents covering the tanezumab molecule have expired or are nearing expiration, this formulation patent can prevent competitors from marketing an identical or highly similar liquid formulation until its expiry. Competitors might be forced to develop alternative formulations or target different therapeutic indications if they wish to enter the market sooner.
-
Biosimilar Differentiation: Biosimilar developers will need to carefully analyze the claims of US 11,833,292. If their proposed biosimilar product has a formulation that falls within the scope of these claims, it could lead to infringement. This may necessitate developing a biosimilar with a subtly different formulation, or seeking a license from the patent holder.
Strategic Considerations for Eli Lilly and Company
-
Strengthened Market Position: The patent reinforces Eli Lilly's market position for tanezumab by protecting a potentially key commercial formulation. This can support pricing strategies and marketing efforts.
-
Defense Against Infringement: The patent provides a legal basis to prevent competitors from launching products that infringe its claims, thereby protecting revenue streams.
-
Licensing Opportunities: The patent could also be a basis for licensing agreements, allowing other companies to utilize the patented formulation in exchange for royalties, under specific terms defined by Eli Lilly.
Strategic Considerations for Competitors
-
Formulation Workarounds: Competitors may need to invest in research and development to create alternative formulations of tanezumab or anti-NGF antibodies that do not infringe on the claims of US 11,833,292. This could involve different excipients, concentrations, pH levels, or even different dosage forms (e.g., lyophilized powder for reconstitution).
-
Patent Challenges: As mentioned, challenging the validity of US 11,833,292 through legal or administrative means could open avenues for market entry if successful.
-
Strategic Partnerships: Competitors might seek partnerships or acquisitions to gain access to intellectual property related to tanezumab or to share the risk and cost of developing competing therapies.
The existence and scope of US 11,833,292 are therefore central to the competitive dynamics surrounding tanezumab. Its expiry date and the precise definition of its claims will dictate the timeline and nature of future market competition.
What Is the Regulatory Status of Tanezumab?
The regulatory status of tanezumab is a critical component influencing its market access and commercial viability, separate from its patent protection. Regulatory approval pathways and decisions by health authorities directly impact the drug's ability to be prescribed and reimbursed.
FDA Review and Approval History
Tanezumab has a complex regulatory history with the U.S. Food and Drug Administration (FDA).
-
Initial Submissions and Delays: Eli Lilly and Pfizer (initially co-developing the drug) submitted New Drug Applications (NDAs) for tanezumab. However, the FDA placed the drug on clinical hold multiple times due to concerns about rapidly progressing osteoarthritis (OA) and joint tissue issues observed in some clinical trial participants. These concerns were primarily related to the mechanism of action, where blocking NGF, crucial for pain signaling, might also affect its role in joint health and maintenance.
-
Resubmission and Advisory Committee Meeting: Following significant efforts to address FDA concerns, including additional clinical trial data and proposed risk mitigation strategies, Eli Lilly resubmitted the NDA for tanezumab (under the brand name Talveyra) for the treatment of moderate-to-severe pain in adult patients with OA. In November 2023, the FDA's Arthritis Advisory Committee reviewed the data. The committee voted overwhelmingly (17-1) against recommending approval, citing persistent safety concerns regarding joint safety and the potential for chondrolysis (rapid joint destruction) and osteonecrosis (bone death).
-
FDA Decision: As of late 2023/early 2024, the FDA has not approved tanezumab for broad OA indication due to these safety concerns. The patent landscape, while granting exclusive rights, is contingent upon regulatory approval for commercial sale.
Global Regulatory Landscape
Tanezumab has also faced scrutiny from other regulatory agencies.
Impact of Regulatory Status on Patent Value
The regulatory hurdles faced by tanezumab significantly influence the commercial value of its patents.
-
Limited Commercial Opportunity: Without regulatory approval for commercial sale, the market exclusivity granted by US 11,833,292 is not fully realized. The ability to generate revenue from the patented formulation is directly dependent on overcoming regulatory barriers.
-
Focus on Specific Indications: If tanezumab eventually gains approval, it may be for highly restricted indications or with stringent risk management plans, limiting its market penetration and the competitive threat it poses. This could affect the strategic importance of specific formulation patents if the approved product is not the one covered by US 11,833,292, or if the approved formulation has a different composition.
-
R&D Investment Justification: The regulatory challenges raise questions about the long-term commercial viability and justify the ongoing R&D investment in this specific molecule and its formulations.
The interplay between patent protection and regulatory approval is crucial for the commercial success of any drug. For tanezumab, the significant regulatory challenges, particularly regarding safety, cast a shadow over the commercial exploitation of its patented intellectual property.
Key Takeaways
- US Patent 11,833,292 grants Eli Lilly and Company exclusive rights to a specific liquid pharmaceutical composition of tanezumab, characterized by defined antibody concentrations, buffer components (histidine, sucrose, polysorbate 80), and pH range (5.0-6.5).
- The patent also claims methods of using this composition to treat various types of pain, including osteoarthritis, chronic low back pain, cancer pain, and inflammatory arthritis.
- This patent, expiring in December 2040, adds a layer of formulation-specific market exclusivity, potentially extending protection beyond earlier molecule patents.
- Competitors seeking to market tanezumab or similar anti-NGF therapies must conduct thorough freedom-to-operate analyses to avoid infringing this patent, which may necessitate developing alternative formulations or challenging patent validity.
- The commercial value of US 11,833,292 is significantly influenced by tanezumab's regulatory status, with ongoing safety concerns (particularly joint-related issues) leading to the FDA's Arthritis Advisory Committee recommending against approval for osteoarthritis pain, impacting potential market realization.
Frequently Asked Questions
-
What is the primary invention protected by US Patent 11,833,292?
The patent protects a specific liquid pharmaceutical composition of tanezumab, detailed by precise concentrations of the antibody and excipients, within a defined pH range, and methods for treating pain using this composition.
-
When does US Patent 11,833,292 expire?
The patent expires on December 5, 2040, barring any patent term extensions or successful challenges.
-
Are there other patents covering tanezumab besides US 11,833,292?
Yes, tanezumab is protected by a portfolio of patents covering its discovery, characterization, manufacturing, and therapeutic uses. US 11,833,292 specifically focuses on a particular formulation.
-
How does the regulatory status of tanezumab affect the value of this patent?
The patent's commercial value is contingent upon regulatory approval of tanezumab for sale. Significant safety concerns and recent FDA advisory committee recommendations against approval for osteoarthritis directly limit the drug's market realization and thus the patent's immediate commercial impact.
-
Can a competitor develop a generic version of tanezumab while this patent is active?
A competitor could potentially develop a generic or biosimilar version if their product does not infringe on the claims of US 11,833,292 or other active tanezumab patents, or if they obtain a license. However, the formulation claims in this patent may restrict the development of identical or highly similar liquid presentations until patent expiry.
Citations
[1] Eli Lilly and Company. (2023). Pharmaceutical preparation containing a monoclonal antibody. U.S. Patent 11,833,292. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
